Mobile

Pharmacokinetic Study to Evaluate Anti-mycobacterial Activity of TMC207 in Combination With Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for Treatment of Children/A...

Mise à jour : Il y a 4 ans
Référence : EUCTR2014-003372-23

Pharmacokinetic Study to Evaluate Anti-mycobacterial Activity of TMC207 in Combination With Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for Treatment of Children/Adolescents Pulmonary MDR-TB

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

- to evaluate the safety and tolerability of TMC207 over a 24-week treatment period in each age cohort. - to evaluate the pharmacokinetics of TMC207 over a 24-week treatment period in the different age cohorts and to provide guidance on dose selection for each of the age cohorts evaluated in this study.

Critère d'inclusion

  • Multi-drug resistant tuberculosis